PDCD1 and pancreatic neoplasm: When paired with the anti-PD-1 antibody nivolumab, ATRA effectively reconfigured the tumor microenvironment, bolstered antitumor immune responses, and markedly curtailed tumor proliferation in murine models of pancreatic cancer (233).